Obermatt
See Similar Stocks →

Aclaris Therapeutics

NSQ:ACRS · US00461U1051
PharmaceuticalsSmall

360

28
Profit price86
Owner Earnings Yield1
Dividend Yield1
Price/Sales35
Price/Book3
Return on Capital7
Cash Return on Capital13
Return on Equity17
Profit margins6
Accruals76
Owner Earnings Margin11
Sales growth23
Profit growth67
Reinvestment89
Price momentum88
Debt load72
Refinancing35
Debt Payback1
Liquidity37
Analyst ratings47
Opinion Changes88
Price Target Upside84
Market mood19
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Aclaris Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2012
Employees64
Websiteaclaristx.com
ISINUS00461U1051
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyRespiratoryChronic DiseasesDermatologyPulmonologyInflammationOncologyBiotechnologyPharmaceuticalTherapeutics

Description

Aclaris Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel small and large molecule product candidates for immuno-inflammatory diseases. The company’s proprietary KINect drug discovery platform, cou…

Analysis

Weak and unloved

Aclaris Therapeutics, Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
34
2023202420252026

All-time high

34

Jun 2026

All-time low

1

Jan 2024

Average rank

18

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
35
3
20
2
Price/Earnings
69
14
14
14
Price/Book
3
53
84
40
Dividend Yield
1
1
1
1
Value (overall)
5
16
47
7

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Aclaris Therapeutics with its peers
Nurix Therapeutics
NMQ:NRIX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Syndax Pharmaceuticals
NSQ:SNDX
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xencor
NMQ:XNCR
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Regeneron Pharmaceuticals
NSQ:REGN
83
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Galectin Therapeutics
NAQ:GALT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Spero Therapeutics
NSQ:SPRO
77
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →